医疗设备制造商Revvity Inc.公布了新一年度财报预期,引发了市场的广泛关注。该公司作出了收入预期的下调,但同时也提高了利润预期并推出新的股票回购计划。
Revvity预计2024财年全年收入将在27.5亿至27.7亿美元之间,较之前预期的27.7亿至27.9亿美元有所下调。这主要是由于生物技术支出减少和美元走强,影响了公司对其药物开发工具和服务的需求。不过,该公司将年度调整后每股收益预期从4.70至4.80美元上调至4.83至4.87美元。
尽管如此,Revvity第三季度营收和利润都超过了分析师预期。该公司利润率和较低税率提振了整体业绩表现。强劲的诊断设备需求是支撑利润增长的主要动力。与此同时,Revvity董事会还批准了一项总额10亿美元、为期两年的新股票回购计划,以取代2023年剩余的6亿美元回购计划,显示出公司对自身前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.